0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cytokines > VEGF-D > VED-H5228

Human VEGF-D Protein, His Tag

  • Synonym
    FIGF,VEGFD
  • Source
    Human VEGF-D, His Tag (VED-H5228) is expressed from human 293 cells (HEK293). It contains AA Phe 93 - Ser 201 (Accession # AAH27948).
    Predicted N-terminus: Phe 93
  • Molecular Characterization
    Online(Phe 93 - Ser 201) AAH27948

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 13.4 kDa. The protein migrates as 19-22 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human VEGF-D, His Tag (Cat. No. VED-H5228) SDS-PAGE gel

Human VEGF-D, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Human VEGF-D, His TagHuman VEGF-D, His Tag (Cat. No. VED-H5228) ELISA bioactivity

Immobilized Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) at 5 μg/mL (100 μL/well) can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with a linear range of 0.08-0.6 μg/mL (QC tested).

Bioactivity-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human VEGF R3, Fc Tag (Cat. No. FL4-H5251) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 19.7 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Bioactivity-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human VEGF R3, His,Avitag (Cat. No. FL4-H82E1) on SA Biosensor, can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 110 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) on SA Biosensor, can bind Human VEGF-D, His Tag (Cat. No. VED-H5228) with an affinity constant of 482 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

  • Background
    Vascular endothelial growth factor D (VEGF-D) is also known as C-fos induced growth factor (FIGF), which belongs to the PDGF / VEGF growth factor family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. This secreted protein VEGF-D / FIGF undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3. The structure and function of this protein is similar to those of VEGFC. FIGF / VEGF-D is highly expressed in lung, heart, small intestine and fetal lung. FIGF / VEGF-D may function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR / FLK1) and VEGFR-3 (FLT4) receptors.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $350.00

Price(USD) : $1980.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:3 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop